Axsome Therapeutics Announces FDA Approval Of AUVELITY, The First And Only Oral NMDA Receptor Antagonist For The Treatment Of Major Depressive Disorder In Adults

Press/Media

Period	19 Aug 2022

Media coverage

Title	Axsome Therapeutics Announces FDA Approval Of AUVELITY, The First And Only Oral NMDA Receptor Antagonist For The Treatment Of Major Depressive Disorder In Adults
Media name/outlet	MENAFN -Press Releases (English)
Country/Territory	Jordan
Date	19/08/22
URL	metabase.moreover.com/noarticleurl?type=psh&lni=66R3-54M1-DY6B-24SD-00000-00
Persons	Dan Vlad Iosifescu